Johnson & Johnson Asset Resilience Ratio
Johnson & Johnson asset resilience ratio. Johnson & Johnson (JNJ) has an Asset Resilience Ratio of 2.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See JNJ defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Johnson & Johnson (1994–2024)
Asset resilience ratio of Johnson & Johnson from 1994 to 2024. This chart shows how Johnson & Johnson's Asset Resilience Ratio has changed over time. Read JNJ total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Johnson & Johnson's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Johnson & Johnson (JNJ) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $5.30 Billion | 2.75% |
| Short-term Investments | $331.00 Million | 0.17% |
| Total Liquid Assets | $5.63 Billion | 2.92% |
Asset Resilience Insights
- Limited Liquidity: Johnson & Johnson maintains only 2.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Johnson & Johnson Industry Peers by Asset Resilience Ratio
Compare Johnson & Johnson's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Johnson & Johnson Asset Resilience Ratio by Year (1994–2024)
Johnson & Johnson asset resilience ratio by year from 1994 to 2024. The table below shows the annual Asset Resilience Ratio data for Johnson & Johnson.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.63% | $6.54 Billion | $180.10 Billion | +0.12pp |
| 2023-12-31 | 3.51% | $5.88 Billion | $167.56 Billion | -4.37pp |
| 2022-12-31 | 7.88% | $14.76 Billion | $187.38 Billion | -2.57pp |
| 2021-12-31 | 10.45% | $19.02 Billion | $182.02 Billion | +2.84pp |
| 2020-12-31 | 7.61% | $13.30 Billion | $174.89 Billion | +4.53pp |
| 2019-12-31 | 3.07% | $4.85 Billion | $157.73 Billion | -0.18pp |
| 2018-12-31 | 3.25% | $4.98 Billion | $152.95 Billion | +0.23pp |
| 2017-12-31 | 3.03% | $4.76 Billion | $157.30 Billion | -18.31pp |
| 2016-12-31 | 21.33% | $30.12 Billion | $141.21 Billion | +2.86pp |
| 2015-12-31 | 18.47% | $24.64 Billion | $133.41 Billion | +4.23pp |
| 2014-12-31 | 14.24% | $18.57 Billion | $130.36 Billion | +8.00pp |
| 2013-12-31 | 6.24% | $8.28 Billion | $132.68 Billion | +1.15pp |
| 2012-12-31 | 5.09% | $6.18 Billion | $121.35 Billion | -1.70pp |
| 2011-12-31 | 6.79% | $7.72 Billion | $113.64 Billion | -1.28pp |
| 2010-12-31 | 8.07% | $8.30 Billion | $102.91 Billion | +4.25pp |
| 2009-12-31 | 3.82% | $3.62 Billion | $94.68 Billion | +1.41pp |
| 2008-12-31 | 2.40% | $2.04 Billion | $84.91 Billion | +0.50pp |
| 2007-12-31 | 1.91% | $1.54 Billion | $80.95 Billion | +1.91pp |
| 2006-12-31 | 0.00% | $1.00 Million | $70.56 Billion | -0.14pp |
| 2005-12-31 | 0.14% | $83.00 Million | $58.86 Billion | -6.76pp |
| 2004-12-31 | 6.90% | $3.68 Billion | $53.32 Billion | -1.69pp |
| 2003-12-31 | 8.59% | $4.15 Billion | $48.26 Billion | -2.71pp |
| 2002-12-31 | 11.30% | $4.58 Billion | $40.56 Billion | +0.35pp |
| 2001-12-31 | 10.95% | $4.21 Billion | $38.49 Billion | +3.71pp |
| 2000-12-31 | 7.24% | $2.48 Billion | $34.24 Billion | +2.04pp |
| 1999-12-31 | 5.20% | $1.52 Billion | $29.16 Billion | +2.31pp |
| 1998-12-31 | 2.89% | $789.00 Million | $27.29 Billion | +2.21pp |
| 1997-12-31 | 0.68% | $146.00 Million | $21.45 Billion | +0.06pp |
| 1996-12-31 | 0.62% | $125.00 Million | $20.01 Billion | +0.19pp |
| 1994-12-31 | 0.43% | $68.00 Million | $15.67 Billion | -- |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more